Financial Comparison: Endologix (ELGX) versus ConforMIS (CFMS)

Endologix (NASDAQ: ELGX) and ConforMIS (NASDAQ:CFMS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Valuation & Earnings

This table compares Endologix and ConforMIS’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Endologix $190.75 million 1.86 -$54.38 million ($0.94) -4.53
ConforMIS $79.26 million 1.92 -$54.78 million ($1.36) -2.50

Endologix has higher revenue and earnings than ConforMIS. Endologix is trading at a lower price-to-earnings ratio than ConforMIS, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Endologix has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, ConforMIS has a beta of 2.25, suggesting that its share price is 125% more volatile than the S&P 500.


This table compares Endologix and ConforMIS’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Endologix -40.77% -46.32% -13.67%
ConforMIS -72.87% -66.61% -49.87%

Analyst Recommendations

This is a summary of recent ratings for Endologix and ConforMIS, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Endologix 0 10 0 0 2.00
ConforMIS 0 4 3 0 2.43

Endologix presently has a consensus target price of $6.33, suggesting a potential upside of 48.67%. ConforMIS has a consensus target price of $8.25, suggesting a potential upside of 142.65%. Given ConforMIS’s stronger consensus rating and higher possible upside, analysts clearly believe ConforMIS is more favorable than Endologix.

Insider & Institutional Ownership

38.6% of ConforMIS shares are owned by institutional investors. 3.9% of Endologix shares are owned by insiders. Comparatively, 9.6% of ConforMIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


ConforMIS beats Endologix on 7 of the 13 factors compared between the two stocks.

Endologix Company Profile

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

ConforMIS Company Profile

ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient’s knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.

What are top analysts saying about Endologix Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endologix Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit